Odin Naderer, PharmD

Odin Naderer, PharmD

September 14, 2020 6:50 pm Published by

Dr. Naderer is currently the Vice President of Clinical Pharmacology and Translational Medicine, a position he has held since 2014. Prior to joining Chimerix, he served as Medicine Development Leader and Senior Scientific Director, within the Infectious Disease Development Unit at GlaxoSmithKline for 15 years. During his tenure at GSK, Dr. Naderer was involved with the approval of two antiretroviral medications and served as the European Federation of Pharmacutical Industries and Associates (EFPIA) Coordinator for the Innovative Medicines Initiative (IMI) funded New Drugs for Bad Bugs Clinical Trial Consortium (COMBACTE) in Europe. Most recently at Chimerix, he was the Principal Investigator on Biomedical Advanced Research and Development Authority (BARDA) contract HHSO100201100013C that was used to support the development and FDA approval of TEMBEXA. TEMBEXA is now included in the strategic national stockpile as a medical countermeasure in the event of a Smallpox outbreak. Dr. Naderer earned a B.S. in Nutrition and Medical Dietetics and his PharmD at the University of Illinois at Chicago, after which he completed a General Practice Residency, an Infectious Disease Specialty Residency and a joint academic/industry Drug Development Fellowship at UNC and GlaxoWellcome

Categorised in:

This post was written by Michelle LaSpaluto